Arylesterase activity of Paraoxonase 1 - prognostic factor for one-year survival in patients with acute myocardial infarction

• Published in: Revista română de medicină de laborator Vol. 26; no. 3; pp. 283 - 292
• Main Authors: Ciumărnean, Lorena, Greavu, Mihai, Vesa, Ştefan C, Tanțău, Alina I, Dogaru, Gabriela B, Alexescu, Teodora G, Milaciu, Mircea V, Saraci, George V, Macarie, Antonia E, Para, Ioana
• Format: Journal Article
• Language: English
• Published: Sciendo 01-07-2018
• Subjects: arylesterase; lactonase; paraoxonase; ST-elevation myocardial infarction; survival
• ISSN: 2284-5623; 2284-5623
• DOI: 10.2478/rrlm-2018-0030

Reduced serum levels of paraoxonase 1 (PON1) activities are associated with diseases involving increased oxidative stress, such as acute coronary syndrome. We aimed to determine whether serum PON1 activities are a prognostic factor for one-year survival following ST-elevation myocardial infarction (STEMI).
We prospectively followed for one-year 75 patients diagnosed and treated for STEMI. Clinical, laboratory and imagistic data were gathered after coronary angiography. PON1 activities (paraoxonase, arylesterase, and lactonase) were assayed spectophotometrically on samples of heparinized plasma taken from the patients in a timeframe of maximum 20 minutes after coronary angiography.
Increased mortality was linked to age (patients over 68 years), permanent atrial fibrillation or left ventricular ejection fraction (LVEF) <40% (associated with global hypokinesia, apical or septal akinesia), trivascular disease atherosclerosis, reduced PON1 activities (paraoxonase <18.4 IU/mL, arylesterase <12.6 IU/mL, lactonase <27.6 IU/mL), and glomerular filtration rate levels <54 mL/min/1.73m2. Multivariate survival analysis showed the independent prognostic role of age (HR 3.92; 95%CI 1.08-14.16; p=0.03), LVEF (HR 9.93; 95%CI 2.20-44.86; p=0.003) and arylesterase (HR 4.25; 95%CI 0.94-19.18; p=0.05) for one-year mortality.
: Reduced arylesterase activity of PON1 is an independent predictor of one-year survival after acute myocardial infarction.